4:00PM 11/12/2014 – 10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston
Reporter: Aviva Lev-Ari, PhD, RN
REAL TIME Coverage of this Conference by Dr. Aviva Lev-Ari, PhD, RN – Director and Founder of LEADERS in PHARMACEUTICAL BUSINESS INTELLIGENCE, Boston http://pharmaceuticalintelligence.com
4:00 p.m. Panel Discussion Novel Approaches to Personalized Medicine
Novel Approaches to Personalized Medicine
Genetic and genomic knowledge is helping the development of new drugs, therapies and prognostic tests. As a result, there are new approaches, new partnerships and new business models that are emerging. In some cases, diseases that were considered incurable not too long ago are now being tackled with highly targeted therapies. In other cases the uncertainties associated with assessing potential aggressiveness of disease are being eliminated. This panel will provide examples of new business paradigms that are emerging from the application of personalized medicine.
Moderator:
Meghan FitzGerald, Ph.D. @cardinalhealth
President, Cardinal Health Specialty Solutions
Chief Genome Officer – next steps in companies, Genomics Index will replace the Biotech Index
Most Interesting person in Genomics: Marc Levin,
Panelists:
2. Chris Garabedian @Sarepta
President and CEO, Sarepta
- Applications of genomics to Infectious diseases, therapeutics – design of drugs, Duchenne Muscular Dystrophy (DMD)
- technology safe working, one drug very effective, 60 alternative drugs, not enough patients to power clinical trials
4. Shawn Marcell
President & CEO, Metamark Genetics
- Prostatic Cancer – Use of genomics tools to diagnose and treat Prostate cancer
- US market is the best for Genomics innovations because venture capital Market is mature, FDA is negotiable, CMP well established
- Business model: platform, good test big market, commercialize, clinical data — PM has a different Business model: Delivery of Test results need to be different
- IPO 2016
1. Scott Schell, M.D., Ph.D. – surgical oncology @KEWGroup
President and CEO, KEW Group
- Large scale platform, strategic partnerships with Oncology Practices,
- Immuno oncologists, repository of data
- 80% of cancers are treated in the community 20% at Academic centers. Integration of knowledge, patients wish to stay in the community
- phase I approval at record high levels
3. Gabriel Bien-Willner, M.D., Ph.D. @MolecularHealth
Medical Director, MolecularHealth, Inc.
- Diagnostics Tools in Analytics. Clinicians do not have the training in Genomics – position firm to create Lab reports and consulting MDs using Analytics for Clinicians
– See more at: http://personalizedmedicine.partners.org/Education/Personalized-Medicine-Conference/Program.aspx#sthash.qGbGZXXf.dpuf
Leave a Reply